Peter Heifetz, Ph.D. is the founder and CEO of OrPro Therapeutics (San Diego, CA). Prior to OrPro, Dr. Heifetz held senior R&D management and corporate development positions at venture-backed companies Rincon Pharmaceuticals (San Diego) and ERA Biotech (Barcelona) and was a Fellow at Diversa Corporation (NASDAQ:DVSA). Dr. Heifetz began his industry career with Ciba-Geigy/Novartis and the Novartis Research Foundation, then transitioned to the global life sciences company Syngenta (NYSE:SYT) following its spinout from Novartis. At Syngenta Dr. Heifetz led world-wide R&D for Syngenta Biopharma and was Director of Consumer Health at the Syngenta Torrey Mesa Research Institute (TMRI) in San Diego. Dr. Heifetz received BS, MS and PhD degrees from Duke University with concentration in Genetics and Biochemical Engineering, and holds a certificate in Innovation Management from the Kenan-Flagler School of Business at the University of North Carolina at Chapel Hill.
1:15 PM–1:30 PM Jun 5, 2018 (US - Eastern)